Kiora Pharmaceuticals Inc
KPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.21M
Close$
$2.03
21.9% downside
Current Fair Value
21.9% downsideOvervalued by 21.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.21 Million |
|---|---|
| Enterprise Value | $1.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.6 |
| Beta | -0.38 |
| Outstanding Shares | 4,174,802 |
Return
| Return on Equity | -79.37% |
|---|---|
| Return on Assets | -52.10% |
| Return on Invested Capital | -30.87% |
Valuation & Multiples
| P/E Ratio | -0.95 |
|---|---|
| PEG | -9.31 |
| Price to Sales | - |
| Price to Book Ratio | 0.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.33 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.86 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 7, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kiora Pharmaceuticals Inc
14 employees
CEO: Stephen From EyeGate Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate's lead product, Ocular Bandage Gel ('OBG'), is b...